Skip to main content
. 2021 Sep 20;11:18587. doi: 10.1038/s41598-021-98131-4

Figure 6.

Figure 6

Exploration of the putative clinical roles of TNFSF4. (A) IHC staining images are shown to clarify different expression patterns (left to right, in sequence, < 25%, 25–75%, and > 75%). A lymph node slide was set as a positive control, and an unstained slide was set as a negative control. (B) High RNA expression of TNFSF4 was universally identified in breast carcinoma, with testing and calculation based on FPKM, and the cutoff line is labeled, which was used for clinical predictions. (C,D) Higher TNFSF4 expression pointed to poorer survival outcomes. (E,F) Flow cytometry with FACSAria sorting was applied to isolate stem cells from ZR75-1, MCF-7, and MM-231 cells. (G,H) Stem cells with a CD44+/24 or ALDH1A1+ phenotype were identified and isolated, and the TNFSF4 expression patterns in different cell lines were checked to illustrate the increased expression.